Johnson & Johnson (JNJ) said Monday that Health Canada authorized lazcluze in combination with rybrevant as a first-line treatment for certain patients with advanced non-small cell lung cancer.
The company said the approval is based on a phase 3 study of the combination in patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations.
The trial showed that the combination reduced the risk of disease progression or death by 30% compared with osimertinib, with a median progression-free survival of 23.7 months versus 16.6 months, according to Johnson & Johnson. The median duration of response was 25.8 months, nine months longer than with osimertinib, the company said.
The drugmaker said its Janssen unit holds marketing authorization for lazcluze and rybrevant in Canada.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。